Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for CLSN
0.270
-0.013 (-4.76%)
After Hours: 0.275 0.000 (0.00%)
Apr 27, 6:38PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.27 - 0.28
52 week 0.19 - 1.70
Open 0.28
Vol / Avg. 0.00/2.55M
Mkt cap 15.01M
P/E     -
Div/yield     -
EPS -0.85
Shares 55.47M
Beta 1.32
Inst. own 9%
May 15, 2017
Q1 2017 Celsion Corp Earnings Release (Estimated) Add to calendar
Mar 16, 2017
Q4 2016 Celsion Corp Earnings Call
Mar 16, 2017
Q4 2016 Celsion Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -4317.27% -4410.75%
Operating margin -4230.64% -4272.13%
EBITD margin - -3924.27%
Return on average assets -63.37% -55.22%
Return on average equity -250.27% -162.69%
Employees 19 -
CDP Score - -

Address

997 Lenox Dr Ste 100
LAWRENCE TOWNSHIP, NJ 08648-2317
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Officers and directors

Jeffrey Wayne Church CPA Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
Age: 58
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Senior Vice President and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Michael H. Tardugno Executive Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Donald Braun Ph.D. Independent Director
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 64
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 68
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters